Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).
Susan F. Slovin(Cornell University), Eric Ostertag(Poseida Therapeutics (United States)), Manjima Dhar(Poseida Therapeutics (United States)), Andreas G. Wibmer(Memorial Sloan Kettering Cancer Center), Christopher E. Martin(Poseida Therapeutics (United States)), Xiao X. Wei(Dana-Farber Cancer Institute), Ann Murphy(Poseida Therapeutics (United States)), Rana R. McKay(University of California San Diego), David Y. Oh(University of California, San Francisco), Joanne McCaigue(Poseida Therapeutics (United States)), Gerald S. Falchook(The University of Texas MD Anderson Cancer Center), Julia Coronella(Poseida Therapeutics (United States)), Majid Ghodussi(Poseida Therapeutics (United States)), Tanya B. Dorff(City Of Hope National Medical Center), Matthew A. Spear(Poseida Therapeutics (United States)), Xīn Gào(Qingdao University), Devon J. Shedlock(Poseida Therapeutics (United States))
Cited by 51
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k